(NASDAQ: UTHR) United Therapeutics's forecast annual revenue growth rate of 5.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.34%.
United Therapeutics's revenue in 2025 is $3,128,400,000.On average, 17 Wall Street analysts forecast UTHR's revenue for 2025 to be $140,838,135,329, with the lowest UTHR revenue forecast at $133,087,947,509, and the highest UTHR revenue forecast at $146,866,059,189. On average, 17 Wall Street analysts forecast UTHR's revenue for 2026 to be $148,760,549,545, with the lowest UTHR revenue forecast at $130,590,664,767, and the highest UTHR revenue forecast at $160,385,831,275.
In 2027, UTHR is forecast to generate $159,912,208,686 in revenue, with the lowest revenue forecast at $134,681,041,672 and the highest revenue forecast at $194,142,204,891.